Browsing Tag: Phase 1 trial

First-in-human trial shows Cyclarity’s UDP-003 can safely bind and excrete 7-ketocholesterol, potentially reversing atherosclerosis. Cyclarity Therapeutics’ UDP-003 achieves first safe removal...